Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Radical -xh acid – or anhydride – acid halide or salt thereof...
Reexamination Certificate
2005-02-04
2010-06-15
Richter, Johann R (Department: 1616)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Radical -xh acid, or anhydride, acid halide or salt thereof...
C514S887000, C514S861000, C554S214000, C560S121000, C560S122000
Reexamination Certificate
active
07737182
ABSTRACT:
A method for or treating xerosis by applying a prostaglandin D receptor selective agonist to a mammal.
REFERENCES:
patent: 4454339 (1984-06-01), Skuballa et al.
patent: 4699920 (1987-10-01), Skuballa et al.
patent: 4789685 (1988-12-01), Skuballa et al.
patent: 4870104 (1989-09-01), Vorbruggen et al.
patent: 4983629 (1991-01-01), Vorbruggen et al.
patent: 5059622 (1991-10-01), Sears
patent: 5491254 (1996-02-01), Sato et al.
patent: 5545666 (1996-08-01), Sato et al.
patent: 5591446 (1997-01-01), Melnik et al.
patent: 5599838 (1997-02-01), Sato et al.
patent: 5807892 (1998-09-01), Klimko et al.
patent: 5852050 (1998-12-01), Melnik et al.
patent: 5891910 (1999-04-01), Buchmann et al.
patent: 6225347 (2001-05-01), Buchmann et al.
patent: 6329539 (2001-12-01), Sato et al.
patent: 6395786 (2002-05-01), Sato et al.
patent: 6506789 (2003-01-01), Sato et al.
patent: 6617353 (2003-09-01), Ito et al.
patent: 6635678 (2003-10-01), Kamm et al.
patent: 6740772 (2004-05-01), Sato et al.
patent: 2004/0266880 (2004-12-01), Sato et al.
patent: 2005/0192357 (2005-09-01), Arai et al.
patent: 0 069 696 (1983-01-01), None
patent: 652211 (1995-05-01), None
patent: 666256 (1995-08-01), None
patent: 737676 (1996-10-01), None
patent: 860430 (1998-08-01), None
patent: 1 084 711 (2001-03-01), None
patent: 1082961 (2001-03-01), None
patent: 1083168 (2001-03-01), None
patent: 1097922 (2001-05-01), None
patent: 1170594 (2002-01-01), None
patent: 1211242 (2002-06-01), None
patent: 1 245 562 (2002-10-01), None
patent: 0 312 601 (2003-05-01), None
patent: 1 314 719 (2003-05-01), None
patent: 1477170 (2004-11-01), None
patent: 7-242622 (1995-09-01), None
patent: 07-242622 (1995-09-01), None
patent: 7-285929 (1995-10-01), None
patent: 07-285929 (1995-10-01), None
patent: 09-71539 (1997-03-01), None
patent: 09-169638 (1997-06-01), None
patent: 09-286775 (1997-11-01), None
patent: 9-286775 (1997-11-01), None
patent: 10-316564 (1998-12-01), None
patent: 11-80031 (1999-03-01), None
patent: 11-199478 (1999-07-01), None
patent: 2000-273083 (2000-10-01), None
patent: 2001-089443 (2001-04-01), None
patent: 2001-122786 (2001-05-01), None
patent: 2001-151749 (2001-06-01), None
patent: 2001-220355 (2001-08-01), None
patent: WO 85/00367 (1985-01-01), None
patent: WO 85/02841 (1985-07-01), None
patent: WO 89/00559 (1989-01-01), None
patent: WO 93/06831 (1993-04-01), None
patent: WO 96/16935 (1996-06-01), None
patent: WO 97/45114 (1997-12-01), None
patent: WO 98/27971 (1998-07-01), None
patent: 99/61029 (1999-02-01), None
patent: 99/61419 (1999-02-01), None
patent: WO 99/25358 (1999-05-01), None
patent: WO 99/62555 (1999-12-01), None
patent: WO 00/32190 (2000-06-01), None
patent: WO 01/19790 (2001-03-01), None
patent: WO 01/19814 (2001-03-01), None
patent: WO 01/49661 (2001-07-01), None
patent: WO 02/16311 (2002-02-01), None
patent: WO 02/20462 (2002-03-01), None
patent: WO 02/045718 (2002-06-01), None
patent: WO 03/070252 (2003-08-01), None
Hellhammer et al., Psychother. Psychosom, 2001, 7, 6-16.
Grant et al., Advanced Drug Delivery Reviews, 2001, 48, 3-26.
Xu et al., J. Invest Dermatol., 2001, 117, 977-983.
Willoughby et al., Lancet, 2000, 255, 646-648.
Merck Manual (http://www.merck.com/mmhe/sec18/ch203/ch203b.html#sb203—1, obtained online on Apr. 17, 2009).
Pons-Guiraud, JEADV, 2007, 21 (Suppl. 2) 1-4.
Angeli, V., et. al., Role of the Parasite-derived Prostaglandin D2in the Inhibition of Epidermal Langerhans Cell Migration during Schistosomiasis Infection, J. Ex. Med. vol. 193, No. 10, May 21, 2001, pp. 1135-1147.
Amendment Under 37 C.F.R. § 1.116 filed Apr. 15, 2008 in U.S. Appl. No. 10/492,948.
The Merck Manual, www.merck.com/mmhe/sec18/ch203/ch203c.html, 2006.
Merriam-Webster Online Dictionary, www.merriam-webster.com/dictionary/preventing, 2005.
Non-Final Office Action dated Dec. 27, 2007 in U.S. Appl. No. 10/493,693.
Final Office Action dated Jan. 15, 2008 in U.S. Appl. No. 10/492,948.
Rosanna Marsella et al., “The ACVD task force on canine atopic dermatitis (XXII): nonsteroidal anti-inflammatory pharmacotherapy”, Veterinary Immunology and Immunopathology, Sep. 20, 2001, vol. 81, No. 3-4, pp. 331-345.
Olivry, T. et al., “Treatment of canine atopic dermatitis with misoprostol, a prostaglandin E1 analogue: An open study”, Database EMBASE [Online] XP002440431, 1997.
Lawrence S. Chan et al., “Expression of Interleukin-4 in the Epidermis of Transgenic Mice Results in a Pruritic Inflammatory Skin Disease: An Experimental Animal Model to Study Atopic Dermatitis”, J. Invest. Dermatol., 2001, 117 pp. 977-983.
Angelika Buske-Kirschbaum et al., “Pyschobiological Aspects of Atopic Dermatitis: An Overview”, Psycotherapy and Psychosomatics, 2001:70:6-16.
Sudha R. Vippagunta et al., “Crystalline Solids”, Advanced Drug Delivery Reviews, (2001), 48, 3-26.
Non-Final Office Action dated Jul. 24, 2007 in U.S. Appl. No. 10/492,948.
Amendment Under 37 C.F.R. §1.111 filed Oct. 24, 2007 in U.S. Appl. No. 10/492,948.
Non-Final Office Action dated May 5, 2208 in U.S. Appl. No. 10/492,498.
Amendment Under 37 C.F.R. § 1.111 filed May 27, 2008 in U.S. Appl. No. 10/493,693.
Final Office Action dated Dec. 16, 2008 in U.S. Appl. No. 10/492,948.
Amendment Under 37 C.F.R. § 1.111, filed Jan. 21, 2009 in U.S. Appl. No. 10/493,693.
Non-Final Office Action dated Aug. 18, 2008, in U.S. Appl. No. 10/493,693.
Amendment Under 37 CFR 1.111, filed Oct. 6, 2008, in U.S. Appl. No. 10/492,948.
Amendment under 37 CFR 1.111 with attachment (Cell, vol. 83, 803-812 [1995]), an executed Rule 132 Declaration of N. Nagahata dated Oct. 27, 2009, and an executed Rule 132 Declaration of I. Arai dated Nov. 4, 2009, in U.S. Appl. No. 10/493,693, as filed on Nov. 9, 2009.
Examiner's Interview Summary dated Nov. 10, 2009, issued in U.S. Appl. No. 10/493,693.
Statement of Substance of Interview as filed in U.S. Appl. No. 10/493,693 on Nov. 24, 2009.
Mark Abramovitz, et al., 'The Utilization of Recombinant Prostanoid Receptors to Determine the Affinities and Selectivities of Prostaglandins and Related Analogs.
Derek A. Willoughby, et al., “COX-1, COX-2, and COX-3 and the furture treatment of chronic inflammatory disease”, The Lancet, vol. 355, pp. 646-648, Feb. 19, 2000.
Non-Final Office Action dated May 14, 2009, in U.S. Appl. No. 10/493,693.
Arai Iwao
Futaki Nobuko
Hashimoto Yuki
Sugimoto Masanori
Fisher Abigail
Fumie Sato
Richter Johann R
Sughrue & Mion, PLLC
Taisho Pharmaceutical Co. Ltd.
LandOfFree
Pharmaceuticals for xerosis does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pharmaceuticals for xerosis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceuticals for xerosis will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4248970